Program

Program Overview and Highlights

Please note that each program title and detail is subject to be updated or changed later.

At JSMO 2024, more than 70% of the presentations were conducted in English, including about 40% of the Keynote Sessions and 80+% of the Oral & Poster Sessions. JSMO 2025 will also welcome participants with many cutting-edge abstracts from Asia and around the world.

The JSMO 2025 program will include:

• A special lecture by Dr. Hisataka Kobayashi from the National Cancer Institute in the USA
• A special lecture by Prof. Ajay Goel from Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope
• A Presidential Symposium featuring the latest topics, including whole genome analysis, liquid biopsy, and artificial intelligence in cancer therapy
• Joint symposiums with ASCO, ESMO, the Asian Pacific Society, and SIOG
• Multiple symposiums highlighting various cancer fields
• Daily rapid oral abstract sessions featuring brief presentations on the most relevant research topics
• Daily poster sessions

• Special Lecture
• Special Session
• Presidential Symposium
• Symposium
• Joint Symposium with International Societies
• Joint Symposium with Japanese Societies
• Educational Lecture
• Committee Program

Special Lecture

Special Lecture 1
Near infrared photoimmunotherapy (NIR-PIT) of cancer

March 6 (Thursday)14:00–15:00
Room 1 (Kobe Portopia Hotel, South Wing 1F Portopia Hall)

Session Information

Chair	Hironobu Minami	(Division of Medical Oncology/Hematology, Graduate School of Medicine, Kobe University)
Speaker	Hisataka Kobayashi	(National Cancer Institute, NIH)

Special Lecture 2
The Era of Liquid Biopsy Biomarkers and Precision Medicine
in Gastrointestinal Cancers

March 7 (Friday)10:20–11:20
Room 1 (Kobe Portopia Hotel, South Wing 1F Portopia Hall)

Session Information

Chair	Tetsuji Takayama	(Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences)
Speaker	Ajay Goel	(City of Hope Comprehensive Cancer Center, City of Hope)

Special Session

March 6 (Thursday)10:40–11:40
Room 3 (Kobe Portopia Hotel, South Wing 1F Ohwada B)

Session Information

Chair	Hironobu Minami	(Division of Medical Oncology/Hematology, Graduate School of Medicine, Kobe University)
Speaker	Oncologists should learn onco-cardiology
	Hironobu Minami	(Division of Medical Oncology/Hematology, Graduate School of Medicine, Kobe University)
	Current status and issues in onco-cardiology practice as revealed by a survey of the Ministry of Health, Labour and Welfare Science Research Fund
	Issei Komuro	(International University of Health and Welfare)

Presidential Symposium

Presidential Symposium 1
Clinical application of whole genome sequencing

March 6 (Thursday)16:10–17:40
Room 1 (Kobe Portopia Hotel, South Wing 1F Portopia Hall)

Session Information

In 2025, whole genome sequencing will be introduced into clinical practice based on the Whole Genome Analysis 2022 Action Plan. We will hear about the current situation in the Netherlands, where clinical implementation has already been realized, and discuss the clinical usefulness of whole genome sequencing.

Chair	Takashi Kohno	(Center for Cancer Genomics and Advanced Therapeutics)
	Edwin Cuppen	(Hartwig Medical Foundation)
Speaker	Whole genome analyses contributing to the prevention, diagnosis, and treatment of lung cancer - Introduction to the Symposium
	Takashi Kohno	(Center for Cancer Genomics and Advanced Therapeutics)
	Clinical Implementation of Whole Genome Sequencing in the Netherlands
	Edwin Cuppen	(Hartwig Medical Foundation)
	The Current State of Clinical Implementation of Whole Genome Sequencing in Japan
	Kuniko Sunami	(National Cancer Center Hospital)
	Clinical applications of whole genome sequencing in childhood cancer
	Motohiro Kato	(Department of Pediatrics, the University of Tokyo)
	Clinical implementation of whole genome sequencing.
	Tatsuhiro Shibata	(Laboratory of Molecular Medicine, The Institute of Medical Science, The University of Tokyo)

March 6 (Thursday)14:00–15:30
Room 2 (Kobe Portopia Hotel, South Wing 1F Ohwada A)

Session Information

Chair	Manabu Muto	(Department of Medical Oncology, Kyoto University Graduate School of Medicine)
	Katsutoshi Oda	(Division of Integrative Genomics, The University of Tokyo)
Keynote Lecture
	Challenges and Future Opportunities in Drug Access for Precision Cancer Medicine in Japan
	Sadakatsu Ikeda	(Institute of Science Tokyo)
Speaker	Off-Label Drug Use under Japanese Health Insurance System
	Tatsuya Suzuki	(National Cancer Center Hospital)
	Current Status of Off-Label Drug Use in Pediatric Oncology
	Junko Takita	(Department of Pediatrics, Graduate School of Medicine, Kyoto University)
	Off-label drug use for cancer patients
	Shinsuke Amano	(Japan Federation of Cancer Patient Groups)
	Health insurance system and new drug coverage in Japan
	Takashi Oshio	(Institute of Economic Research, Hitotsubashi University)

March 6 (Thursday)10:10–11:40
Room 7 (Kobe International Conference Center B1/1F Main Hall)

Session Information

The “drug lag” problem, where drug development in Japan is delayed, has been greatly alleviated through the shortening of review periods. However, as Japan's relative market size shrinks and venture companies take the lead in development, a new issue, “drug loss,” has emerged, where certain drugs are not developed in Japan. This results in patients in Japan, a developed country, being unable to access the latest treatments, which has significant repercussions. The “drug loss” of antineoplastic agents, in particular, poses a life-or-death issue for patients, making urgent countermeasures essential.
The Ministry of Health, Labour and Welfare has introduced various measures, such as strengthening innovation evaluations in drug pricing and omitting phase I trials in Japan before entering international clinical trials. However, to effectively resolve the issue of drug loss while ensuring the efficacy and safety of drugs for Japanese patients, further concrete solutions need to be explored in collaboration with academia and industry. For instance, in the field of antineoplastic drugs, U.S. venture companies have been reported to bypass development in Japan, prioritizing rapid market entry in the U.S. and neglecting Japan's regulatory and drug pricing systems.
Additionally, the “Report on Pharmaceutical Affairs Regulations for Strengthening Drug Discovery Capabilities and Ensuring Stable Supply,” compiled by the Ministry of Health, Labour and Welfare in April of Reiwa 6, outlines cases where it may be appropriate to grant regulatory approval without clinical trial results in Japanese patients. This approach is intended to minimize the disadvantages Japanese patients face due to delays caused by additional clinical trials. The report emphasizes the importance of gathering as much information as possible on the administration of drugs to Japanese patients, reviewing this data during the regulatory process, and providing the medical community with relevant information. It also suggests using the conditional approval system to allow for the submission of clinical trial results involving Japanese patients after market approval.
Thus, this symposium will focus on solutions to overcome the drug loss problem while ensuring the efficacy and safety of drugs for Japanese patients. In particular, we will discuss the conditional approval system and its recent revisions, as outlined in the notifications issued on October 23, 2024, regarding its application to rare diseases. The goal is to identify strategies that can effectively address the issue of drug loss.

Chair	Kan Yonemori	(Department of Medical Oncology, National Cancer Center Hospital)
	Kiyohito Nakai	(Ministry of Health, Labor and Welfare)
Speaker	From the standpoint of academia
	Taizo Hirata	(Clinical Research Center in Hiroshima, Hiroshima University Hospital)
	From the Perspective of Biostatistics and Regulatory Science
	Akihiro Hirakawa	(Department of Clinical Biostatistics, Institute of Science Tokyo)
	Utilizing and Improving the Conditional Approval System from the Perspective of Patient Benefits
	Yoshiyuki Majima	(NPO PanCAN Japan)
	From the industry's perspective
	Takashi Owa	(Eisai Co., Ltd.)
	Making everyone's lives brighter together ~From the Regulator's Perspective~
	Toyotaka Iguchi	(Pharmaceuticals and Medical Devices Agency)

Presidential Symposium 4
ctDNA-guided cancer therapy

March 7 (Friday)8:20–9:50
Room 1 (Kobe Portopia Hotel, South Wing 1F Portopia Hall)

Session Information

Chair	Yasushi Sato	(Department of Community Medicine for Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences)
	François-Clément Bidard	(Institut Curie)
Speaker	Beyond the Knife: ctDNA's Promise in Post-Surgery Colorectal Cancer Management
	Yoshiaki Nakamura	(National Cancer Center Hospital East)
	Adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer
	Jeanne Tie	(Peter MacCallum Cancer Centre, Walter & Eliza Hall Institute of Medical Research)
	From avant-garde to clinical routine: intercepting and targeting ESR1 mutation-mediated resistance in ER+ metastatic breast cancer
	François-Clément Bidard	(Institut Curie)
	Development and perspective of ctDNA-guided therapy in lung cancer
	Eiji Iwama	(Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University)
	ctDNA analysis for urothelial carcinoma
	Shusuke Akamatsu	(Department of Urology, Nagoya University Graduate School of Medicine)

March 8 (Saturday)10:10–11:40
Room 2 (Kobe Portopia Hotel, South Wing 1F Ohwada A)

Session Information

With the promotion of genomic medicine, the existence of familial tumors is now considered more important than ever. In rare cancers, familial tumors are even more important than other carcinomas, and this is why we have included them in this symposium.

Chair	Akihiro Sakurai	(Department of Medical Genetics and Genomics, Sapporo Medical University School of Medicine)
	Makoto Hirata	(Department of Genetic Medicine and Services, National Cancer Center Hospital)
Speaker	Clinical practice and perspectives on hereditary breast and ovarian cancer for breast cancer oncologists
	Masahiko Tanabe	(The Department of Breast and Endocrine Surgery, The University of Tokyo Hospital)
	Current and past treatment strategies for Von Hippel-Lindau (VHL) disease in Japan
	Eijiro Nakamura	(National Cancer Center Hospital Japan)
	Mucocutaneous Lesions of Cowden Syndrome
	Yoshiaki Kubo	(Department of Dermatology, Tokushima University Graduate School of Medical Science)
	Li-Fraumeni syndrome surveillance and cancer treatment
	Hiroyoshi Hattori	(Department of Clinical Genetics, NHO Nagoya Medical Center)
	Current status and latest information on medical management of Lynch syndrome
	Takeshi Nakajima	(Osaka International Cancer Institute)

March 8 (Saturday)14:00–15:30
Room 2 (Kobe Portopia Hotel, South Wing 1F Ohwada A)

Session Information

Chair	Eishi Baba	(Department of Comprehensive Oncology, Kyushu University)
	Manabu Muto	(Department of Medical Oncology, Kyoto University Graduate School of Medicine)
Speaker	Multicenter clinical trial to evaluate the utility of CGP prior to initial systemic therapy in advanced solid tumors (NCCH1908:UPFRONT trial)
	Takaaki Mizuno	(Department of Experimental Therapeutics, National Cancer Center Hospital/Genomics Unit, Keio Cancer Center, Keio University School of Medicine)
	The first-line comprehensive genomic profiling of advanced solid tumors: 1-year follow-up data of the FIRST-Dx study
	Junichi Matsubara	(Department of Medical Oncology, Kyoto Univ. Graduate School of Medicine)
	The significance and optimal timing of comprehensive genomic profiling test in patients with metastatic breast cancer
	Ippei Fukada	(Genomic Medicine, Cancer Institute Hospital of the Japanese Foundation for Cancer Research)
	Should cancer gene panel testing be carried out before starting the first-line treatment for patients with mCRPC?
	Hiroshi Kitamura	(Department of Urology, Faculty of Medicine, University of Toyama)
	TBD
	TBD	(TBD)

Presidential Symposium 7
New molecular-targeted therapy for colorectal cancers

March 8 (Saturday)8:30–10:00
Room 4 (Kobe Portopia Hotel, South Wing 1F Ohwada C)

Session Information

Chair	Takayuki Yoshino	(National Cancer Center Hospital East)
	Kei Muro	(Department of Clinical Oncology, Aichi Cancer Center Hospital)
Speaker	Tucatinib plus trastuzumab for HER2-positive, RAS wild-type metastatic colorectal cancer
	John H. Strickler	(Duke University, Duke Cancer Institute)
	Trastuzumab-Deruxtecan for HER2 positive colorectal cancer
	Hisato Kawakami	(Department of Clinical Oncology, Tohoku University Graduate School of Medicine)
	Sotorasib Plus Panitumumab for Colorectal Cancer with KRAS G12C Mutation
	Tae-Won Kim	(Asan Medical Center)
	New treatment option for salvage line Colorectal cancer: Fruquintinib
	Taroh Satoh	(Center for Cancer Genomics and Precision Medicine, Osaka University Hospital)
	Optimal therapy to target BRAF mutated colorectal cancer
	Kopetz Scott	(The University of Texas MD Anderson Cancer Center)

Symposium

Gastrointestinal Oncology

Symposium 1
New multimodal treatment strategy for GI cancer

March 6 (Thursday)8:30–10:00
Room 2 (Kobe Portopia Hotel, South Wing 1F Ohwada A)

Session Information

In addition to conventional cancer treatments such as surgery, radiation, and chemotherapy, immunotherapy has become an established treatment strategy. Furthermore, the options for immunotherapy and molecular targeted therapy have become more diversified. Additionally, the development of new diagnostic methods using ctDNA and others is indispensable for the advancement of treatment. By making use of these approaching, these approaches, treatment strategies aimed at achieving long-term survival, cure, and organ preservation are being attempted. In this session, experts will discuss the future perspectives from thier own positions.

Chair	Izuma Nakayama	(Gastrointestinal Oncology, National Cancer Center Hospital East)
	Elizabeth Smith	(Oxford Cancer)
Keynote Lecture
	Redefining the Path to Cure: The Rise of Non-Operative Management in Upper GI Cancer
	Izuma Nakayama	(Gastrointestinal Oncology, National Cancer Center Hospital East)
	NONOPERATIVE MANAGEMENT IN LOWER GI CANCERS
	Filippo Pietrantonio	(Fondazione IRCCS Istituto Nazionale dei Tumori)
Discussant	Filippo Pietrantonio	(Fondazione IRCCS Istituto Nazionale dei Tumori)
	Yukihide Kanemitsu	(Department of Colorectal Surgery, National Cancer Center)
	Yoshiaki Nakamura	(National Cancer Center Hospital East)
	Hiroki Osumi	(Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research)
	Itaru Yasufuku	(Department of Clinical Anatomy Development Studies, Gifu University Graduate School of Medicine)

Symposium 20
New treatments on the horizon for the upper GI cancers

March 8 (Saturday)10:10–11:40
Room 3 (Kobe Portopia Hotel, South Wing 1F Ohwada B)

Session Information

Share findings and discuss future perspectives on emarging therapies for upper GI cancers

Chair	Daisuke Takahari	(Department of Medical Oncology, Gunma University Graduate School of Medicine)
	Hanneke W.M. van Laarhoven	(Department of Medical Oncology, Amsterdam UMC)
Speaker	New HER2 - Targeted Therapies
	Sylvie Lorenzen	(Department of Hematology and Oncology, Klinikum rechts der Isar)
	Claudin-18.2 as a new therapeutic target in upperGI cancer
	Hanneke W.M. van Laarhoven	(Department of Medical Oncology, Amsterdam UMC)
	Expanding the horizon of immunotherapy combinations in mismatch repair proficient advanced gastric cancer
	Ian Chau	(Royal Marsden Hospital)
	Treatment Strategies for MSI-H Gastric Cancer
	Yukiya Narita	(Department of Clinical Oncology, Aichi Cancer Center Hospital)
	The recent trend of early-development trials in Upper Gastrointestinal Cancers
	Shigehiro Koganemaru	(Department of Experimental Therapeutics, National Cancer Center Hospital East)

Hepatobiliary and Pancreatic Oncology

Symposium 9
Perioperative treatment for resectable/Borderline resectable pancreatic cancer

March 7 (Friday)8:20–9:50
Room 3 (Kobe Portopia Hotel, South Wing 1F Ohwada B)

Session Information

To review current treatment strategies for the perioperative management of resectable and borderline resectable pancreatic cancer in different countries and explore future perspectives in this field.

Chair	Masato Ozaka	(Cancer Institute Hospital, Japanese Foundation for Cancer Research)
	Li-Tzong Chen	(Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University/National Intsitute of Cancer Research, National Health Research Institutes, Tainan)
Panelist	Teresa Macarulla	(Vall d¡'Hebron University Hospital)
	Li-Tzong Chen	(Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University/National Intsitute of Cancer Research, National Health Research Institutes, Tainan)
	Do-Youn Oh	(Seoul National University Hospital)
	Shuichi Aoki	(Department of Surgery, Tohoku University Graduate School of Medicine)

Symposium 10
Is GC plus immune checkpoint inhibitor or GC plus S-1 the first-line systemic therapy for unresectable biliary tract cancer?

March 7 (Friday)9:50–11:20
Room 3 (Kobe Portopia Hotel, South Wing 1F Ohwada B)

Session Information

The discussion will focus on how GC+S-1 developed in Japan can be positioned compared to the global standard GC plus immune checkpoint inhibitor.

Chair	Makoto Ueno	(Department of Gastroenterology, Kanagawa Cancer Center)
	Do-Youn Oh	(Seoul National University Hospital)
Speaker (Pro)
	TBD
	Robin Kate Kelley	(University of California, San Francisco)
	First-line systemic therapy for unresectable biliary tract cancer: GC + immune checkpoint inhibitors or GC + S-1?
	Chigusa Morizane	(Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital)
Speaker (Con)
	Gemcitabine and cisplatin (GC) plus ICI compared with GC plus S-1 for patients with advanced biliary tract cancer (KHBO2201-YOTSUBA): a phase 3 trial
	Tatsuya Ioka	(Department of Oncology Center, Yamaguchi University Hospital)
	Treatment option for cure in the patients with unresectable biliary tract cancer -GCS vs. GC+IO-
	Etsuro Hatano	(Department of Surgery, Kyoto University)
Oversight by the Chair

Thoracic Oncology

Symposium 11
New treatment strategy for NSCLC with oncogenic driver mutation

March 7 (Friday)15:00–16:30
Room 4 (Kobe Portopia Hotel, South Wing 1F Ohwada C)

Session Information

The prognosis in lung cancer patients has dramatically improved with the clinical introduction of genomic medicine and immunotherapy such as ICI. On the other hand, such therapies have already reached their limits, and new breakthrough therapy are needed. In this symposium, we will discuss the current status of genomic medicine, which contributes significantly to the therapeutic outcome of lung cancer, and the future direction of therapeutic development.

Chair	Satoshi Oizumi	(Department of Respiratory Medicine, NHO Hokkaido Cancer Center)
	Toshiyuki Kozuki	(National Hospital Organization Shikoku Cancer Center)
Speaker	Treatment for EGFR-mutated patients after EGFR-TKI failure
	Solange Peters	(Lausanne University Hospital)
	Treatment strategies for EGFR exon20 ins mutation-positive lung cancer
	Junko Tanizaki	(Department of Medical Oncology, Kindai University Faculty of Medicine)
	Development of novel targeted therapy for lung cancer with rare oncogenic driver
	Hiroki Izumi	(Department of Thoracic Oncology, National Cancer Center Hospital East)
	TBD
	Daniel SW Tan	(National Cancer Centre Singapore)
	Perioperative Treatment for Resectable EGFR-Mutant NSCLC
	Shun Lu	(Department of Medical Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China)

Symposium 22
Development of new technologies for lung cancer

March 8 (Saturday)10:10–11:40
Room 4 (Kobe Portopia Hotel, South Wing 1F Ohwada C)

Session Information

Leading experts from both domestic and international arenas, who are active at the forefront of their fields, come together to discuss the latest technologies and findings in the realm of lung cancer. Physicians involved in clinical development from around the world will present on the latest advancements in ADC/Bi-specific Antibody, the evolution of T cell engager technology, and an overview and potential of TTField Therapy. In addition, the current state of developments in pathological diagnosis through AI and radiological image diagnosis will be introduced, and the challenges ahead will be discussed.

Chair	Hidetoshi Hayashi	(Department of Medical Oncology, Kindai University Faculty of Medicine)
	Takehito Shukuya	(Department of Respiratory Medicine, Juntendo University School of Medicine)
Speaker	ADC/Bi-specific Antibody
	Byoung Chul Cho	(Yonsei Cancer Center, Yonsei University College of Medicine)
	Advances in DLL3-Targeted T-Cell Engagers: Revolutionizing Therapy for Small-Cell Lung Cancer and Neuroendocrine Tumors
	Tatsuya Yoshida	(Department of Thoracic Oncology, National Cancer Center Hospital)
	TTField Therapy in NSCLC
	Ticiana Leal	(Emory University)
	Innovative Approaches in Pathological Assessment
	Takuo Hayashi	(Department of Human Pathology, Juntendo University School of Medicine)
	State-of-the-Art Lung Cancer Imaging
	Yoshiharu Ohno	(Department of Diagnostic Radiology, Fujita Health University School of Medicine)

Hematology Oncology

Symposium 3
Cutting edge of genomic medicine and novel therapy in hematologic malignancies

March 6 (Thursday)8:30–10:00
Room 4 (Kobe Portopia Hotel, South Wing 1F Ohwada C)

Session Information

International session regarding the cutting edge of genomic medicine and novel therapy in hematologic malignancies (malignant lymphoma and leukemia)

Chair	Kennosuke Karube	(Department of Pathology and Laboratory Medicine, Nagoya University School of Medicine)
	Yosuke Minami	(Department of Hematology, National Cancer Center Hospital East)
Speaker	Utilization of cancer genome medicine in the pathological diagnosis of lymphoid neoplasms
	Kennosuke Karube	(Department of Pathology and Laboratory Medicine, Nagoya University School of Medicine)
	From Biomarker Discovery to Clinical Decision Making: Multi-Omic Approaches in Non-Hodgkin Lymphoma (NHL)
	Nathan Fowler	(BostonGene, Corp.)
	Genomic profiling and Precision Medicine for Leukemia Therapy
	Yosuke Minami	(Department of Hematology, National Cancer Center Hospital East)
	Novel therapy based on genomic analysis in leukemia
	Jorge E Cortes	(Georgia Cancer Center)

Symposium 27
Current state and future direction of immunotherapies in malignant lymphoma and multiple myeloma

March 8 (Saturday)10:10–11:40
Room 7 (Kobe International Conference Center B1/1F Main Hall)

Session Information

Immunotherapies against malignant lymphoma (ML) and multiple myeloma (MM) have significantly improved prognosis in patients with ML and MM. Development of CAR-T cell therapies as well as bispecifi antibodies has drawn attention to further improve their outcomes. To select the best choice of anti-ML and -MM therapies, we need to deeply understatnd the current state of immunotherapies in Japan and also novel modalies of CAR-T and bispecific antibodies.

Chair	Kentaro Fukushima	(Department of Hematology and Oncology, Osaka University Graduate School of Medicine)
	Wee-Joo Chng	(National University of Singapore)
Speaker	Bipecific Antibodies in Treatment of B-cell Lymphoma
	Grzegorz Stanislaw Nowakowski	(Mayo Clinic)
	CAR T-cell therapy for aggressive B-cell lymphomas in earlier line setting
	Shinichi Makita	(Department of Hematology, National Cancer Center Hospital)
	Facilitating CAR-T cell therapy in the treatment of lymphoma and myeloma: effective operation of cell therapy.
	Kentaro Fukushima	(Department of Hematology and Oncology, Osaka University Graduate School of Medicine)
	Development of immunotherapies to better control multiple myeloma: how to maximize their efficacy
	Takeshi Harada	(Department of Hematology, Endocrinology and Metabolism, Tokushima Graduate School of Biomedical Sciences)

Breast cancer

Symposium 14
How to use ADCs in metastatic /recurrent breast

March 7 (Friday)8:20–9:50
Room 7 (Kobe International Conference Center B1/1F Main Hall)

Session Information

Antibody-drug conjugates (ADCs) have revolutionized the practice of metastatic and recurrent breast cancer. HER2 and Trop2 are now available as target molecules, and ADCs for various targets such as HER3 and B7H4 will emerge in the future. On the other hand, the increase in treatment options has raised new issues. Specifically, what is the optimal therapy, what is the optimal sequencing and combination therapy, and appropriate adverse event management. More than ever, management considerations must be based on clinical trial data and real-world data on drugs. In this session, four experts will discuss the latest ADCs, combination therapy, sequencing, adverse event management, and resistance mechanisms and how to overcome them, sharing with us the profound world of cutting-edge ADC development for breast cancer.

Chair	Junji Tsurutani	(Advanced Cancer Translational Research Institute, Showa University)
	Shanu Modi	(Memorial Sloan Kettering Cancer Center)
Panelist	Ayumi Saito	(Department of Medical Oncology, National Cancer Center Hospital)
	Paolo Tarantino	(Dana-Farber Cancer Institute)
	TBD	(TBD)
	Aleix Prat	(Hospital Clinic Barcelona, FRCB-IDIBAPS)

Symposium 19
Not too little, not too much : Optimizing more vs. less treatment
for older patients with breast cancer

March 8 (Saturday)8:30–10:00
Room 2 (Kobe Portopia Hotel, South Wing 1F Ohwada A)

Session Information

De-staging may be a better option for older patients with curable early-stage breast cancer, taking into account their general condition. Collaborative decision making, which aims to facilitate decision making in line with patient values, can guide health care providers and patients in complex decisions to optimize breast cancer treatment. This session will discuss optimal surgery, radiation, drugs, and risk assessment for breast cancer in the elderly, taking into account risk-benefit considerations.

Chair	Hiroshi Ishiguro	(Saitama Medical University International Medical Center)
	Giuseppe Curigliano	(European Institute of Oncology, IRCCS and University of Milano)
Keynote Lecture
	Not too little, not too much: optimizing more versus. less treatment for older patients with breast cancer
	Etienne Brain	(Institut Curie and UVSQ)
Panelist	Yasuaki Sagara	(Department of Breast and Thyroid Surgical Oncology, Sagara Hospital)
	Akihiko Shimomura	(National Center for Global Health and Medicine)
	Yuichiro Kikawa	(Department of Breast Surgery, Kansai Medical University)

Gynecologic Oncology

Symposium 6
New drug treatments for gynecological cancers

March 6 (Thursday)8:30–10:00
Room 7 (Kobe International Conference Center B1/1F Main Hall)

Session Information

Chair	Kan Yonemori	(Department of Medical Oncology, National Cancer Center Hospital)
	Jae-Weon Kim	(Seoul National University)
Speaker	TBD
	TBD	(TBD)
	State of Art Treatment of Advanced and Recurrent Endometrial Cancer: Immunotherapy and Beyond
	Shannon N Westin	(University of Texas MD Anderson Cancer Center)
	New Drug Treatments for Ovarian Cancer
	Kathleen N Moore	(Stephenson Cancer Center at OU Health)

Urological Oncology

Symposium 23
Treatment strategy for mRCC 2025: Is HIF-2α inhibitor a game changer?

March 8 (Saturday)14:00–15:30
Room 4 (Kobe Portopia Hotel, South Wing 1F Ohwada C)

Session Information

1st line treatment strategy for mRCC is still controversial. Long followup results of IO combination regimens revealed some problems; limited efficacy of IO combination regimen for primary site, low efficacy of IO combination regimens in favorable risk patients, and worsened HR of OS in IO-TKI regimens, showing the need of further breakthrough for better survival of mRCC patients. In this program, latest topics of 1st line treatment for mRCC will be presented, especially focusing on HIF-2α inhibitor as a next promising drug for mRCC.

Chair	Thomas Powles	(Centre for Experimental Cancer Medicine, Barts Cancer Institute)
	Masayuki Takahashi	(Department of Urology, Tokushima University Graduate School of Biomedical Sciences)
Speaker	The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in modern era
	Ken-ichi Tabata	(Department of Urology, Kitasato University Kitasato Insititute Hospital)
	Treatment strategy for mRCC: Is HIF-2alpha inhibitor a game changer?
	Ravindran Kanesvaran	(National Cancer Centre Singapore)
	Combined immunotherapy for advanced renal cell carcinoma. When IO/IO and when IO/TKI?
	Kohji Takemura	(Department of Medical Oncology, Toranomon Hospital)
	HIF-2 Alpha Inhibitors - Game Changers?
	Eric Jonasch	(UT MD Anderson Cancer Center)
Oversight by the Chair
	Thomas Powles	(Centre for Experimental Cancer Medicine, Barts Cancer Institute)

Head and Neck Cancer

Symposium 2
Current Status and Prospects of Treatment Strategies for Thyroid Cancer

March 6 (Thursday)10:10–11:40
Room 2 (Kobe Portopia Hotel, South Wing 1F Ohwada A)

Session Information

Drug therapy for thyroid cancer has mainly used sorafenib and lenvatinib, which are multi-kinase inhibitors, but serpercatinib, which targets RET mutations and fusion genes, has been added. In addition, development of therapies for BRAF gene mutations is underway, which is expected to lead to major advances in personalized medicine.
We will learn and discuss the latest information from Japan and abroad on treatment strategies for thyroid cancer, which is becoming more complex with increasing treatment options, and the future prospects for personalized medicine.

Chair	Tomoya Yokota	(Division of Gastrointestinal Oncology, Shizuoka Cancer Center)
	Hisham Mehanna	(InHANSE, College of Medicine and Health, University of Birmingham)
Speaker	Recent updates in molecular targeted agents for thyroid cancer
	Bhumsuk Keam	(Department of Internal Medicine, Seoul National University Hospital)
	Current status of systemic therapy for radioiodine-refractory differentiated thyroid cancer
	Naoki Fukuda	(Department of Medical Oncology, The Cancer Institute Hospital of JFCR)
	Current status and future perspectives on the treatment of anaplastic thyroid caner
	Tomohiro Enokida	(Department of Head and Neck Medical Oncology, National Cancer Center Hospital East)
	Current Status and Prospects of Treatment Strategies for Thyroid Cancer in Japan
	Ken-ichi Ito	(Division of Breast and Endocrine Surgery, Department of Surgery, Shinshu University School of Medicine)

Rare Cancer

Symposium 29
Rare cancers with promising drugs in the future

March 8 (Saturday)10:10–11:40
Room 8 (Kobe International Conference Center 3F International Conference Room)

Session Information

Treatment strategies for rare cancers, as with other types of cancer, are moving in the direction of personalized medicine. In this context, we will discuss promising drugs that will soon be available for use in practical practice for each cancer types of rare cancers.

Chair	Takafumi Koyama	(Department of Experimental Therapeutics, National Cancer Center Hospital)
	Akihiro Nishiyama	(Department of Medical Oncology, Kanazawa University Hospital)
Speaker	The current status and future of EZH2 inhibitors in epithelioid sarcoma or other rare solid tumors.
	Tatsunori Shimoi	(Department of Medical Oncology, National Cancer Center Hospital)
	Current status of PDGFR inhibitors in GIST
	Toshihiko Doi	(National Cancer Center Hospital East)
	Development of ALK inhibitors for ALK fusion gene-positive solid tumors, including inflammatory myofibroblast tumors (IMT)
	Toshiki Masuishi	(Department of Clinical Oncology, Aichi Cancer Center Hospital)
	Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma -Brigimadlin (BI-907827)-
	Akira Kawai	(Department of Musculoskeletal Oncology and Rehabilitation Medicine, National Cancer Center Hospital)
	Promising Future Treatments for Brain Tumors: Precision Medicine and Gene Therapy
	Kazuhiko Kurozumi	(Department of Neurosurgery, Hamamatsu University School of Medicine)

Translational Research/Clinical Pharmacology)

Symposium 7
How do we select the partner for the combination immunotherapy?

March 6 (Thursday)8:30–10:00
Room 8 (Kobe International Conference Center 3F International Conference Room)

Session Information

Cancer immunotherapy has entered the era of combined immunotherapy from that of single-agent immunotherapy, and various combination therapies have been introduced, but some of them are used with few basic rationales. In this symposium, we will review the basic backgrounds and discuss how combination therapies are used in clinical practice, especially in lung cancer, which can help us to select the best partner for combination therapies.

Chair	Yosuke Togashi	(Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University)
	Yasushi Goto	(Thoracic Oncology, National Cancer Center Hospital)
Speaker	How Do We Select the Partner for Combination Immunotherapy?
	Yosuke Togashi	(Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University)
	The role of cytotoxic chemotherapy in combination immunotherapy
	Kiichiro Ninomiya	(Center for Comprehensive Genomic Medicine, Okayama University Hospital)
	CTLA-4: Established Target, Next Antibodies, and Persistent Unknowns
	Hidetoshi Hayashi	(Department of Medical Oncology, Kindai University, Faculty of Medicine)
	The role of anti-angiogenic therapy in tumor immunity
	Satoru Miura	(Niigata Cancer Center Hospital)
	Strategic Partnering in Cancer Immunotherapy
	Yasushi Goto	(Thoracic Oncology, National Cancer Center Hospital)

Symposium 15
Companion diagnosis required for pathology

March 7 (Friday)8:20–9:50
Room 8 (Kobe International Conference Center 3F International Conference Room)

Session Information

When molecular pathology targets are used, molecular pathology diagnosis by pathologists is required as a companion diagnosis for immunohistochemical staining and/or FISH. In this symosium, we will have some presentations on various molecular pathology diagnoses for various cancer types, which can be useful for the collaboration between clinicians and pathologists.

Chair	Yasushi Yatabe	(Department of Diagnostic Pathology, National Cancer Center Hospital)
	Satoshi Fujii	(Department of Molecular Pathology, Yokohama City University Graduate School of Medicine)
Speaker	Companion diagnostics for treatment of lung cancer patients
	Yasushi Yatabe	(Department of Diagnostic Pathology, National Cancer Center Hospital)
	Companion diagnostics required for breast cancer treatment, focusing on HER2 and PD-L1 testing
	Masayuki Yoshida	(Department of Diagnostic Pathology, National Cancer Center Hospital)
	Companion diagnostics required for digestive cancer
	Satoshi Fujii	(Department of Molecular Pathology, Yokohama City University Graduate School of Medicine)
	Ancillary Pathology Testing in the Systemic Treatment of Salivary Gland Cancers: Focusing on Companion Diagnosis
	Toshitaka Nagao	(Department of Anatomic Pathology, Tokyo Medical University)

Symposium 16
Advances and Challenges in development of Novel Therapies Based on TR Research

March 7 (Friday)15:00–16:30
Room 8 (Kobe International Conference Center 3F International Conference Room)

Session Information

Advanced cancer drug therapy has made remarkable progress with the discovery of various driver oncogenes and the development of their inhibitors. However, disease progression due to resistance remains a significant challenge, and translational research aimed at overcoming this problem will continue to be crucial in the future. In this symposium, both basic and translational researchers will present their latest findings and discuss the remaining issues for further enhancing cancer treatment in the future.

Chair	Tadaaki Yamada	(Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine)
	Ryohei Katayama	(Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research)
Speaker	Alterations in cancer cells and cancer associated cells in the tumor microenvironment inducing drug resistance in ALK-rearranged NSCLC
	Ryohei Katayama	(Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research)
	Resistance mechanisms to KRAS G12C inhibitors and novel therapeutic strategies targeting RAS
	Kenichi Suda	(Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine)
	Genomic screening for the development of novel targeted therapy in rare oncogenic driver-positive lung cancer
	Shingo Matsumoto	(Department of Thoracic Oncology, National Cancer Center Hospital East)
	Therapeutic strategies to overcome resistance in EGFR mutation-positive lung cancer.
	Eiji Iwama	(Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University)

Palliative Care/Symptom Management

March 7 (Friday)8:20–9:50
Room 5 (Kobe Portopia Hotel, South Wing B1F Topaz)

Session Information

Chair	Asao Ogawa	(Department of Psycho-Oncology Service, National Cancer Center Hospital East)
	Ayako Mori	(Nursing Department, National Cancer Center Hospital)
Chair's Presentation
	Asao Ogawa	(Department of Psycho-Oncology Service, National Cancer Center Hospital East)
Speaker	Considering Treatment for Cancer Patients with Dementia Who Have Difficulty Understanding the Benefits and Harms of Treatment
	Masakazu Abe	(Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine)
	Advance care planning for selection of recuperation place in cancer patients.
	Takeshi Yoshida	(Palliative Care Center and Department of Medical Oncology, Kindai University Hospital)
	Should chemical coping be accepted in patients with advanced cancer? How should we approach it?
	Hideaki Hasuo	(Department of Psychosomatic Medicine, Kansai Medical Univrsity)
	Introduction of Abuse Cases and Issues in Cancer Hospitals ~The Role of Medical Institutions and Conflicts of Medical Professionals~
	Rieko Shimizu	(Center for Physician Referral and Medical Social Service, National Cancer Center Hosptal)

March 7 (Friday)9:50–11:20
Room 5 (Kobe Portopia Hotel, South Wing B1F Topaz)

Session Information

Chair	Eriko Satomi	(Department of Palliative Medicine, National Cancer Center Hospital)
	Akira Inoue	(Department of Palliative Medicine, Tohoku University School of Medicine)
Speaker	Promotion of nerve blocks for refractory cancer pain and buildng a community medical coordination system
	Yoshihisa Matsumoto	(Department of Palliative Therapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research)
	Regional and in-hospital collaboration system for palliative radiotherapy
	Takeo Takahashi	(Department of Radiation Oncology, Saitama Medical Center, Saitama Medical University)
	Initiatives to promote the use of palliative interventional radiology
	Miyuki Sone	(Department of Diagnostic Radiology/Interventional Radiology Center, National Cancer Center Hospital)
	Multidisciplinary strategies to develop cancer pain management algorithm and enhance the quality of cancer pain relief.
	Keita Tagami	(Yushoukai Home Medical Clinic Nerima)

March 8 (Saturday)8:30–10:00
Room 5 (Kobe Portopia Hotel, South Wing B1F Topaz)

Session Information

Chair	Kazuhiro Yanagihara	(Department of Medical Oncology, Kansai Electric Power Hospital)
	Tomohiro Inui	(Cancer Management Center, Tokushima University Hospital)
Speaker	Strategies and research for the prevention of chemotherapy-induced peripheral neuropathy.
	Akiko Hanai	(Chiba University Faculity of Informatics)
	Management of Chemotherapy Induced Peripheral Neuropathy -Evidence for Drug Therapy-
	Yoichiro Yoshida	(Center for Medical Informatics and Data Science, Fukuoka University Hospital)
	Efficacy of acupuncture for Chemotherapy-Induced Peripheral Neurotoxicity in breast cancer survivors
	Hiroto Ishiki	(Department of Palliative Medicine, National Cancer Center Hospital)
	Medical devices for chemotherapy-induced peripheral neuropathy
	Emi Kubo	(National Cancer Center Hospital East)
	Management of chronic cancer pain involving nociplastic pain
	Toshiari Kawai	(Department of Psycho-Oncology, Cancer Institute Hospital of JFCR)

Cross-sectional Program

March 7 (Friday)15:00–16:30
Room 13 (Kobe International Exhibition Hall, Hall No.2 Building 2F 2A Meeting Room)

Session Information

Chair	Kenji Tamura	(Department of Medical Oncology, Shimane University Hospital)
	Ryuji Hayashi	(Clinical Oncology, Toyama University Hospital)
Speaker	The Landscape of Immune Checkpoint-Targeted Antibodies: From Key Properties to Breakthrough Developments
	Yuji Miura	(Cancer Institute Hospital of JFCR)
	Bispecific antibodies in cancer immunotherapy
	Shingo Yano	(Division of Clinical Oncology and Hematology, The Jikei University School of Medicine)
	Innovation in Antibody-Drug Conjugates
	Fumikata Hara	(Department of Breast Oncology, Aichi Cancer Center)
	Other New Antibody Therapies
	Rinpei Niwa	(Kyowa Kirin Co., Ltd.)

March 8 (Saturday)14:00–16:30
Room 3 (Kobe Portopia Hotel, South Wing 1F Ohwada B)

Session Information

Chair	Maki Tanioka	(Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine)
	Kenji Hirata	(Department of Diagnostic Imaging, Faculty of Medicine, Hokkaido University)
Speaker	Reporting patient summaries from electronic medical records using large-scale language models and generative AI
	Gen Tamiya	(Tohoku University School of medicine/RIKEN Center for Advanced Intelligence Project)
	An Explainable Deep Learning Model and Spatial Gene Expression Platform to Discover Novel Drug Targets for Anti-cancer drugs
	Maki Tanioka	(Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine)
	Biological feature extraction of histopathology images for multimodal analysis.
	Shumpei Ishikawa	(Department of Preventive Medicine, Graduate School of Medicine, The University of Tokyo / Division of Pathology, Exploratory Oncology Research & Clinical Trial Center Pathology, National Cancer Center)
	Clinical Application of Medical AI: Focusing on the research and development of AI-based medical devices
	Ryuji Hamamoto	(National Cancer Center Research Institute)
	Support System for Cytodiagnosis Using Artificial Intelligence for 3D Image Recognition
	Ken'ichi Morooka	(Faculty of Advanced Science and Technology, Kumamoto University)

March 8 (Saturday)8:30–10:00
Room 7 (Kobe International Conference Center B1/1F Main Hall)

Session Information

Chair	Yasutoshi Kuboki	(Department of Experimental Therapeutics, National Cancer Center Hospital East)
	Toshio Shimizu	(Department of New Experimental Therapeutics, International Cancer New Drug Development Center, Kansai Medical University Hospital/NEXT Oncology KMU JAPAN/NEXT Oncology, TX USA)
Speaker	Current situation and future prospects/issues of newly developed drugs (general discussion)
	Shigehisa Kitano	(The Cancer Institute Hospital of JFCR)
	Current status and prospects of Tissue Agnostic Drug Development in Oncology
	Megumi Ishiguro	(Health Science Research & Development Center (HeRD), Institute of Science Tokyo)
	Diversity in drug development
	Takako Nakajima	(Kyoto University Graduate School of Medicine)
	Japan's perspective in early development of anticancer drugs
	Noboru Yamamoto	(National Cancer Center Hospital)

Multidisciplinary Team Program

March 6 (Thursday)8:30–10:00
Room 5 (Kobe Portopia Hotel, South Wing B1F Topaz)

Session Information

Chair	Tetsuhiro Yoshinami	(Center for Cancer Genomics and Personalized Medicine, Osaka University Hospital)
	Chie Watanabe	(Showa University School of Nursing & Rehabilitation Sciences)
Keynote Lecture
	Issues and problems with bone metastasis cancer boards
	Hiroyuki Shibata	(Akita University Graduate School of Medicine)
Speaker	Transdisciplinary management of skeletal metastasis in cancer patients
	Tatsuya Takagi	(Palliative Medicine/Orthopedics/Rehabilitation Medicine, Juntendo University)
	The Role of Radiation Oncologists in Bone Metastasis Conferences
	Hisayasu Nagakura	(Department of Radiology, KKR Sapporo Medical Center)
	As active role of rehabilitation therapists at the meeting of multiple professionals for the patient with bone metastasis
	Kazunari Abe	(Department of Rehabilitation Sciences, Honamino -sato Clinic)
	The Role of Nurses in the Multidisciplinary Management of Bone Metastasis in Cancer
	Shinobu Uto	(Department of Nursing, Keio University Hospital)
	Let's make it happen in the hospital! ~Know-how to organize a bone metastasis conference ~.
	Teruhisa Azuma	(Nara Prefecture General Medical Center)

March 6 (Thursday)14:00–15:30
Room 5 (Kobe Portopia Hotel, South Wing B1F Topaz)

Session Information

Chair	Tomonobu Koizumi	(Nagano Prefectural Kiso Hospital)
	Junya Sato	(Shonan University of Medical Science)
Keynote Lecture
	How to implement feasible and evidence-based chemotherapy regimen
	Koji Matsumoto	(Division of Medical Oncology/ Clinical Genetics, Hyogo Cancer Center)
Speaker	The Role of Pharmacists in Managing Cancer Chemotherapy Regimens
	Yasunari Okuda	(Department of Pharmacy, Jichi Medical University Hospital)
	Incorporating safe administration management from a nurse's perspective into regimen reviews
	Youta Yatagai	(Nursing Department, Tochigi Cancer Center)
	Effectiveness of Dietitian Interventions in Cancer Chemotherapy Review Committee
	Hideki Yanome	(Aizawa Hospital of Jisenkai Healthcare Incorporated Foundation)
	Possible roles of pharmacists in health insurance pharmacies with disclosure of drug dosage regimens by hospitals
	Toshiki Nakamura	(Akebono Pharmacy Group, Akebono Pharmacy)
	Pharmaceutical management leading to the AI hospital projects
	Hisanori Shimizu	(Department of Pharmacy, Japanese Foundation for Cancer Research, Cancer Institute Hospital)

Symposium 25
Optimization of long-term health management of childhood and adolescent cancer survivors:how can we support their transition to adult care?

March 8 (Saturday)14:00–15:30
Room 5 (Kobe Portopia Hotel, South Wing B1F Topaz)

Session Information

Although the importance of long-term follow-up and transitional support for late complications in survivors who experienced cancer treatment during childhood and adolescence is being recognized, sufficient system development is not yet in place.
This project aims to discuss the long-term health management of survivors, incorporating perspectives from the individuals themselves and their family doctors. We will report on the current status and challenges in medical aspects while discussing future directions.

Chair	Chikako Shimizu	(Department of Breast and Medical Oncology, National Center for Global Health and Medicine)
	Hatoe Sakamoto	(National Cancer Center Hospital East)
Speaker	My utilization of long-term follow up and primary care - From the perspective of a childhood cancer survivor-
	Daisuke Masumoto	(Childhood Cancer Association in Japan)
	Challenges of Transitional Support for Childhood Cancer Survivors
	Kimikazu Matsumoto	(Children's Cancer Center, National Center for Child Health and Development)
	Approaches to Transition Support in Adult Health Care -NCGM Transition Care Program-
	Tomoko Taniyama	(National Center for Global Health and Medicine)
	Building partnerships between cancer centers and local medical institutions for long-term health management of cancer survivors
	Satoshi Kanke	(Department of General Internal Medicine and Family Medicine, Fukushima Medical University)
Special Remarks
	Yuka Kato	(Department of Nursing, Shizuoka Children Hospital)
Commentator
	Bradley J. Zebrack	(University of Michigan Rogel Cancer Center and School of Social Work)

Clinical Trial Facilitation Program

Symposium 8
Challenges for implementation of translational research in clinical trials

March 6 (Thursday)14:00–15:30
Room 8 (Kobe International Conference Center 3F International Conference Room)

Session Information

Translational Research (TR) is an approach that swiftly applies findings from basic research to the clinical forefront, serving as a key to enhancing the quality of patient care. Recently, TR methodologies have seen remarkable advancements, contributing to the development of more effective treatment strategies at various stages of clinical trials. However, when it comes to essential requirements for promoting TR, such as specimen collection in clinical trials and the introduction of novel technologies, Japan is notably lagging behind other countries. This symposium aims to invite domestic experts and leading figures in international TR research to explore challenges and opportunities for the development and implementation of new therapeutic methods and TR.

Chair	Yoshiaki Nakamura	(National Cancer Center Hospital East)
	Yu Sunakawa	(Department of Clinical Oncology, St. Marianna University School of Medicine)
Speaker	Multiomics analysis using a large-scale sample set from clinical trials
	Hiromichi Ebi	(Aichi Cancer Center)
	Translational Research in Early Drug Development
	Takafumi Koyama	(National Cancer Center Hospital)
	Translational research in gastrointestinal cancer using clinical samples
	Akihito Kawazoe	(National Cancer Center Hospital East)
	Challenges for implementation of translational research in large scale investigator-initiated clinical trials
	Chigusa Morizane	(National Cancer Center Hospital)
	Spatial architecture of tumor microenvironment and therapeutic responses
	Woong-Yang Park	(GxD Inc.)

Symposium 28
Current updates to learn about clinical trial modernization

March 8 (Saturday)8:30–10:00
Room 8 (Kobe International Conference Center 3F International Conference Room)

Session Information

The costs—both in terms of human resources, time, and finances—associated with the development of new treatments have been increasing yearly. As a result, efforts to optimize and streamline clinical trials with the aim of cost reduction have been gaining momentum. In the field of cancer treatment development, new evaluation metrics, such as differences in restricted mean survival time (RMST) in situations where survival curves diverge later (reflecting delayed survival benefits), along with the utilization of real-world data, adaptive designs, and Bayesian designs, are prime examples of such efforts. This symposium will discuss the latest domestic and international trends in these new frameworks for clinical trials.

Chair	Hideharu Yamamoto	(Chugai Pharmaceutical Co., Ltd.)
	Kenichi Nakamura	(Department of International Clinical Development, National Cancer Center Hospital)
Speaker	Summarizing Treatment Effects on Survival Time: Issues with Traditional Hazard Ratios and New Approaches
	Hajime Uno	(Dana-Farber Cancer Institute)
	Newer statistical designs for non-inferiority trials
	Shogo Nomura	(The University of Tokyo, Graduate School of Medicine)
	Opportunities and Challenges of Complex Innovative Trial Designs
	Martin Posch	(Medical University of Vienna)
	The impact of adaptive design on clinical trials
	Hideki Suganami	(Kowa co., ltd.)

March 8 (Saturday)14:00–15:30
Room 8 (Kobe International Conference Center 3F International Conference Room)

Session Information

Chair	Hidehito Horinouchi	(Department of Thoracic Oncology, National Cancer Center Hospital)
	Shogo Nomura	(Graduate School of Medicine, The University of Tokyo)
Speaker	SCRUM-MONSTAR & CIRCULATE-Japan platform to accelerate precision oncology innovations; achievement and perspective
	Takayuki Yoshino	(National Cancer Center Hospital East)
	Perspectives on New Clinical Trial Endpoints Using Molecular Residual Disease Testing
	Hideaki Bando	(National Cancer Center Hospital East)
	Key points for evaluation in clinical trials using MRD and future challenges
	Akinari Tsukada	(Pharmaceuticals and Medical Devices Agency)
	Issues and perspectives on MRD-based clinical development in thoracic oncology
	Hidehito Horinouchi	(Department of Thoracic Oncology, National Cancer Center Hospital)

Patient Advocacy/Survivorship

March 7 (Friday)8:20–9:50
Room 13 (Kobe International Exhibition Hall, Hall No.2 Building 2F 2A Meeting Room)

Session Information

Chair	Kiyotaka Watanabe	(Division of Medical Oncology, Department of Medicine, School of Medicine, Teikyo University)
	Yukari Tsubata	(Shimane University Hospital)
Keynote Lecture
	Report of the Research Group for the Development of Educational Programs for the Promotion of Patient and Public Involvement in Cancer Research
	Etsuko Aruga	(Department of Palliative Medicine, Teikyo University School of Medicine)
	Nothing about us, without us
	Naomi Sakurai	(CSR Project, General Incorporated Association)
Panelist	Maiko Higuchi	(Division of Nursing, Toyama University Hospital)
	Kayoko Katayama	(Faculty of Informatics, Gunma University)
	Jiichiro Sasaki	(Division of Clinical Oncology, Department of Comprehensive Medicine, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine)

Joint Symposium with International Societies

ASCO/JSMO

ASCO/JSMO Joint Symposium
Drugging the Undruggable Targets

March 6 (Thursday)16:00–17:30
Room 7 (Kobe International Conference Center B1/1F Main Hall)

Session Information

In this session, we aim to share information on the latest advancements in cancer treatment development, including new drugs in early-line therapy and emerging biomarker research.

Chair	Lynn Schuchter	(ASCO - Chair of Board, University of Pennsylvania - Director, Tara Miller Melanoma Center)
	Hironobu Minami	(Medical Oncology/Hematology, Kobe University Graduate School of Medicine)
Speaker	Breaking Barriers: Advances in targeting the "undruggable" proteins in oncology
	Erika P. Hamilton	(Sarah Cannon Research Institute)
	Unlocking Undraggable Targets: from Mission Impossible to Mission Achievable
	Anna Spreafico	(Princess Margaret Cancer Centre, University Health Network)
	SCRUM-MONSTAR Multiomics Platform: Advancing Precision Medicine through Novel Cancer Therapeutics
	Hideaki Bando	(National Cancer Center Hospital East)
	The development of drugs targeting RNA splicing mechanisms in anti-cancer therapy
	Takafumi Koyama	(National Cancer Center Hospital)

ESMO/JSMO

ESMO/JSMO Joint Symposium
Economic Issues in Cancer Care

March 7 (Friday)9:50–11:20
Room 7 (Kobe International Conference Center B1/1F Main Hall)

Session Information

Cancer care is a field with many topics that require discussion, including the timing of CGP, subsequent treatment strategies, and the growing research on whole Genome sequencing, which is also being advanced in Japan. We believe that discussing the situation in Europe would provide valuable insights.

Chair	Solange Peters	(Lausanne University Hospital)
	Kan Yonemori	(Department of Medical Oncology, National Cancer Center Hospital)
Speaker	TBD
	Raffaela Casolino	(World Health Organization)
	Systematic genomic characterisation of cancers in 2024: worth the cost?
	Isabell Durant Zaleski	(University of Paris, APHP)
	Economic issues in precicion oncology
	Kuniko Sunami	(Department of Laboratory Medicine, National Cancer Center Hospital)
	How to maximize the utilization of genomic information from comprehensive genomic profiling (CGP) and genetic tests?
	Katsutoshi Oda	(The University of Tokyo)

Asian Pacific Society/JSMO

Asian Pacific Society Symposium
Education for Oncologists

March 7 (Friday)15:00–16:30
Room 7 (Kobe International Conference Center B1/1F Main Hall)

Session Information

The promotion of international cooperation to lead to the development of region-specific cancer treatment and prevention methods.

Chair	Kazuki Sudo	(Department of Medical Oncology, National Cancer Center)
	Ravindran Kanesvaran	(National Cancer Centre Singapore)
Speaker	International cooperation to lead to the development of region-specific cancer treatment
	Do-Youn Oh	(Seoul National University Hospital)
	TBD
	Janice Tsang	(Hong Kong Breast Oncology Group (HKBOG))
	Educaton program for Japanese medical oncology
	Takahiro Kogawa	(Cancer Institute Hospital of JFCR)
	International collaboration to lead to the development of region-specific cancer treatment and prevention methods: an oncologist's perspective
	Shigenori Kadowaki	(Department of Clinical Oncology, Aichi Cancer Center Hospital)

SIOG/JSMO

SIOG/JSMO Joint Symposium
Lessons to Learn from the Leading Nations in Geriatric Oncology

March 6 (Thursday)14:00–15:30
Room 7 (Kobe International Conference Center B1/1F Main Hall)

Session Information

Given the feedback from participants in previous symposiums, there has been a strong interest in understanding the clinical practices and research in countries leading the field of geriatric oncology, such as France and Belgium. Therefore, we will invite speakers from France and Belgium to present the latest advancements and innovations in geriatric oncology. Alongside these presentations, we aim to clarify what Japan is doing well, where it may be lacking, and discuss the direction in which Japanese geriatric oncology should advance.

Chair	Tomonori Mizutani	(Department of Medical Oncology, Kyorin University Faculty of Medicine)
	Hiroshi Yamamoto	(Department of Respiratory Medicine, Tokyo Metropolitan Institute for Geriatrics and Gerontology)
Speaker	Current Status and Issues in Geriatric Oncology in Japan.
	Hiroshi Yamamoto	(Department of Respiratory Medicine, Tokyo Metropolitan Institute for Geriatrics and Gerontology)
	Organizing Cancer Care for Older Adults: France's Strategic Oncogeriatric Initiative
	Rabia Boulahssass	(UCOG PACA EST Teaching Hospital of Nice France, University of Nice Sophia Antipolis)
	Implementation of geriatric assessment in Belgium
	Hans Wildiers	(University Hospitals Leuven)
	Collaboration of Oncology and Geriatrics
	Ken Sugimoto	(Geriatric General Medicine, Kawasaki Medical School)

Joint Symposium with Japanese Societies

Japanese Cancer Association (JCA)/Japan Society of Clinical Oncology (JSCO)/Japanese Society of Medical Oncology (JSMO)

Joint Symposium 1
JCA/JSCO/JSMO initiatives for precision oncology

March 6 (Thursday)8:30–10:30
Room 3 (Kobe Portopia Hotel, South Wing 1F Ohwada B)

Session Information

Chair	Takashi Kohno	(C-CAT, National Cancer Center)
	Manabu Muto	(Department of Medical Oncology, Kyoto University Graduate School of Medicine)
	Seiji Yano	(Department of Respiratory Medicine, Kanazawa University)
Speaker	Biomarkers for CLK inhibitor CTX-712 treatment response in myeloid neoplasms: Paving the way toward clinical trials
	Seishi Ogawa	(Department of Pathology and Tumor Biology, Kyoto University)
	Elucidation of the Resistance Mechanisms to Cancer Immunotherapy
	Hiroyoshi Nishikawa	(Division of Cancer Immunology, Research Institute, National Cancer Center Japan)
	Prospects for navigation surgery using AI technology
	Masaaki Ito	(National Cancer Center Hospital East)
	Longitudinal Tumor-Informed ctDNA Dynamics for Monitoring Tumor Burden in Advanced Cancers
	Satoshi Nishizuka	(Iwate Medical University Institute for Biomedical Sciences)
	Development of novel CAR-T cell therapy: from blood cancers to solid tumors
	Yozo Nakazawa	(Department of Pediatrics, Shinshu University School of Medicine)
	Development of a novel antibody-drug conjugate with a CAF-mediated mechanism of action targeting Glypican-1
	Tetsuji Naka	(Division of Allergy and Rheunatology, Department of Internal Medicine, School of Medicine Iwate Medical University, Institute for Biomedical Science of Iwate Medical University)

Japanese Circulation Society (JCS)/Japanese Onco-Cardiology Society (JOCS)/Japanese Society of Medical Oncology (JSMO)

March 6 (Thursday)15:30–17:30
Room 3 (Kobe Portopia Hotel, South Wing 1F Ohwada B)

Session Information

Chair	Yuko Tanabe	(Toranomon Hospital)
	Yoshihiro Fukumoto	(Cardiovascular Medicine, Kurume University School of Medicine)
Speaker	Differences between oncologists and cardiologists regarding the indications for invasive treatment of cardiovascular disease in cancer patients
	Mikio Mukai	(Osaka Center for Cancer and Cardiovascular Disease Prevention)
	Cancer care and follow-up: When to consult a cardiologist
	Yoichi Naito	(Department of General Internal Medicine, National Cancer Center Hospital East)
	The role of hematologists in providing care to patients with cardio-oncology problems
	Kazuhiro Bandai	(Hyogo Prefectural Amagasaki General Medical Center)
	Cancer associated thrombosis: Multidisciplinary collaboration and follow-up
	Yoshihiro Tanaka	(Gastroenterological Surgery, Gifu University)
	Enhancing Efficiency in Cardio-Oncology Clinics: Addressing the Growing Burden of CV Complications in Cancer Patients
	Tatsuhiro Shibata	(Kurume University School of Medicine, Department of Internal Medicine, Division of Cardiovascular Medicine)
	A Cardiovascular Interventionalist's Perspective
	Yoshihisa Nakagawa	(Department of Cardiovascular Medicine, Shiga University of Medical Science)

Japan Society of Human Genetics (JSHG)/Japanese Society of Medical Oncology (JSMO)

March 6 (Thursday)14:00–16:00
Room 4 (Kobe Portopia Hotel, South Wing 1F Ohwada C)

Session Information

Chair	Issei Imoto	(Aichi Cancer Center Research Institute)
	Katsuya Tsuchihara	(EPOC, National Cancer Center Japan)
Speaker	Cancer Genomic Medicine in Japan
	Akira Chiba	(Ministry of Health, Labour and Welfare)
	Guidance for hereditary cancer syndrome with multigene panel testing (MGPT) ver. 2025
	Akira Hirasawa	(Department of Clinical Genomic Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University)
	Presumed Germline Pathogenic Variant
	Takeshi Kuwata	(National Cancer Center Hospital East)
	Significance and future prospects for clinical implementation of whole genome sequencing
	Motohiro Kato	(Department of Pediatrics, the University of Tokyo)
	Expectation for clinical implementation of MGPT and Patient and public involvement in MGPT
	Izumi Okawara	(Japanese NF1 patient group named as To Smile)

Japanese Society of Hematolog (JSH)/Japanese Society of Medical Oncology (JSMO)

Joint Symposium 4
Recent Advances and Future Perspectives of Cellular Immunotherapy -CAR T-cell and T-cell engager-

March 7 (Friday)15:00–17:00
Room 3 (Kobe Portopia Hotel, South Wing 1F Ohwada B)

Session Information

Chair	Takanori Teshima	(Hematology, Hokkaido University)
	Dai Maruyama	(Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research)
Speaker	Recent updates and future outlook of CAR-T cell technology
	Koji Tamada	(Department of Immunology, Yamaguchi University Graduate School of Medicine/Research Institute for Cell Design Medical Science, Yamaguchi University)
	Development of a non-viral gene transfer platform for CAR-T manufacturing from academia to international clinical research
	Yoshiyuki Takahashi	(Department of Pediatrics, Nagoya University Graduate School of Medicine)
	Development of next-generation T cell therapy for hematological malignancies and beyond
	Miki Ando	(Department of Hematology, Juntendo University School of Medicine)
	Current Status and Prospects for the Clinical Development of Cell-Based Immunotherapy for Solid Tumors
	Shigehisa Kitano	(The Cancer Institute Hospital of JFCR)
	Cellular Immunotherapy (CAR-T, BTE) for Lymphoid Malignancies: Ongoing Clinical Trials and Future Perspectives
	Koji Izutsu	(National Cancer Center Hospital)

Japanese Society of Cancer Nursing (JSCN)/Japanese Society of Medical Oncology (JSMO)

March 7 (Friday)8:20–10:20
Room 4 (Kobe Portopia Hotel, South Wing 1F Ohwada C)

Session Information

Chair	Kaori Yagasaki	(Faculty of Nursing and Medical Care, Keio University)
	Koji Matsumoto	(Division of Medical Oncology, Hyogo Cancer Center)
Keynote Lecture
	Advancing Geriatric Oncology: Insights into Japan's Current Landscape and Future Directions
	Tomonori Mizutani	(Department of Medical Oncology, Kyorin University Faculty of Medicine)
Speaker	Comprehensive Geriatric Assessment in oncology : practice at NHO Kyushu Cancer Center
	Kohei Arimizu	(Geriatric Oncology Service, the Department of Gastrointestinal and Medical Oncology, NHO Kyushu Cancer Center)
	Support for the treatment and recuperation of elderly cancer patients, with dignity
	Sawa Fujita	(Faculty of Nursing, University of Kochi)
	Decision making support for elderly cancer patients
	Risako Unoki	(Nursing Department, Yokohama Municipal Citizen's Hospital)

Japanese Orthopaedic Association (JOA)/Japanese Society of Medical Oncology (JSMO)

March 7 (Friday)15:00–17:00
Room 9 (Kobe International Conference Center 4F 401+402)

Session Information

Chair	Akira Kawai	(Department of Musculoskeletal Oncology and Rehabilitation Medicine, National Cancer Center Hospital)
	Hiroyuki Shibata	(Department of Clinical Oncology, Akita University Graduate School of Medicine)
Speaker	Why orthopaedics is indispensable to the bone metastasis cancer board: Revolutionizing cancer care through the novel field, onco-orthopaedics
	Hirotaka Kawano	(Department of Orthopaedic Surgery, Teikyo University School of Medicine)
	Bone Metastasis Cancer Board in Community Medicine: Current Status and Future Vision
	Teruhisa Azuma	(Nara Prefecture General Medical Center)
	Implementation of temporal subtraction CT for prevention and early intervention of Skeletal-Related Events (SRE)
	Shigemi Matsumoto	(Department of Real World Data R & D, Graduate School of Medicine, Kyoto University)
	Management of bone metastases to prevent paralysis
	Eiji Nakata	(Department of Orthopedic Surgery, Okayama University Hospital)
	Interventional Radiology and medical collaboration in the treatment of bone metastases
	Yasunori Arai	(Department of Diagnostic Radiology, National Cancer Center Hospital East)
	Challenges in Multidisciplinary Collaboration for Bone Metastases: A Radiation Oncologist's Perspective
	Kei Ito	(Department of Radiation Oncology, Tokyo Metropolitan Komagome Hospital)
	Bone Metastasis Cancer Board and its Challenges in Japan
	Eisuke Kobayashi	(Department of Muscloskeletal Oncology, National Cancer Center Hospital)
	Cancer Board for Bone Metastasis: Approaches and Challenges for Social Implementation
	Hideo Morioka	(Department of Orthopaedic Surgery, National Hospital Organization Tokyo Medical Center)

Japanese Society for Radiation Oncology (JASTRO)/Japanese Society of Medical Oncology (JSMO)

March 8 (Saturday)8:30–10:30
Room 6 (Kobe Portopia Hotel, South Wing B1F Emerald)

Session Information

Chair	Hitoshi Ikushima	(Department of Therapeutic Radiology, Tokushima University Graduate School)
	Sadamoto Zenda	(Department of Radiation Oncology, National Cancer Center Hospital East)
Speaker	Concept of oligometastasis and the effectiveness of local treatment
	Katsuyuki Shirai	(Department of Radiation Oncology, Jichi Medical University Hospital)
	Stereotactic body radiotherapy for lung metastases
	Yasuo Matsumoto	(Department of Radiation Oncology, Niigata Cancer Center Hospital)
	Stereotactic Body Radiotherapy for oligo-bone metastases
	Kei Ito	(Department of Radiation Oncology, Tokyo Metropolitan Komagome Hospital)
	Follow-up and management after treatment for oligometastatic disease
	Taiji Koyama	(Medical Oncology/Hematology, Kobe University Hospital)

Japanese Society for Palliative Medicine (JSPM)/Japanese Society of Medical Oncology (JSMO)

March 8 (Saturday)14:00–16:00
Room 7 (Kobe International Conference Center B1/1F Main Hall)

Session Information

Chair	Eriko Satomi	(Department of Palliative Medicine, National Cancer Center Hospital)
	Harue Arao	(Osaka University Graduate School of Medicine)
Speaker	Effective and efficient decision-making support for patients with advanced cancer using digital technology
	Maiko Fujimori	(National Cancer Center)
	Applying Decentralized Clinical Trials in the Supportive and Palliative Care
	Tatsuo Akechi	(Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences)
	Digital technology to support treatment and care for adolescent and young adult (AYA) patients with cancer
	Yuki Kojima	(National Cancer Center Hospital)
	AI Development in Cancer Palliative Care
	Masanori Mori	(Seirei Mikatahara General Hospital)
	Application of virtual reality (VR) in supportive and palliative care
	Kazuyuki Niki	(The University of Osaka Graduate School of Pharmaceutical Sciences)

Educational Lecture

Committee Program

March 6 (Thursday)8:30–10:00
Room 14 (Kobe International Exhibition Hall, Hall No.2 Building 3F 3A Meeting Room)

Session Information

Chair	Makoto Ueno	(Department of Gastroenterology, Kanagawa Cancer Center)
	Minoru Fukuda	(Japanese Red Cross Nagasaki Genbaku Isahaya Hospital)
Speaker	TBD
	Kota Katanoda	(Institute for Cancer Control, National Cancer Center)

Session Information

Chair	Shigehisa Kitano	(Department of Advanced Medical Development, The Cancer Institute of JFCR)
Speaker	Fact-Checking Cancer Information on Social Media in Japan
	Nari Kureyama	(Toyokawa City Hospital Breast Surgery)
	Utilization of SNS in Medical Oncology Seminars for Medical Students and Residents
	Daisuke Ogiya	(Department of Hematology and Oncology, Tokai University School of Medicine)
	Bridging Divides in Medical Communication on Social Media: Building Trust Beyond Confrontation
	Noboru Hagino	(Division of Rheumatology, Teikyo University Medical Center in Chiba)

Committee Program 2
Educational activities on Medical Oncology in Asia-Pacific region

March 6 (Thursday)10:10–11:40
Room 14 (Kobe International Exhibition Hall, Hall No.2 Building 3F 3A Meeting Room)

Session Information

In recent years, innovative cancer drug therapies have been developed one after another, and cancer treatment is advancing at a dramatic pace. There are many excellent academic organizations in Asia-Pacific countries that aim to promote and further advance such cancer care. The Asia-Pacific region is very diverse in terms of ethnicity, social systems, and health insurance systems, even though the regions are relatively close to each other. This is no exception in the educational systems, academic programs, and educational activities related to medical oncology. In this session, we will have speakers from the education-related committees of MOGA, CSCO, KSMO, SSO, and TOS, which have been contributing to oncology education in the Asia-Pacific region, in collaboration with JSMO in various ways. The aim is to discuss the efforts and future prospects of each society, and also to promote mutual understanding among the Asia-Pacific region in terms of medical oncology education.

Chair	Ichiro Kinoshita	(Division of Clinical Genomics, Department of Medical Oncology, Hokkaido University Hospital)
	Hidehito Horinouchi	(Department of Thoracic Oncology, National Cancer Center Hospital)
Speaker	Oncology Education Initiatives at Medical Oncology Society in theAsia-Pacific Region - Medical Oncology Group of Australia.
	Melissa Eastgate	(Medical Oncology Group of Australia)
	TBD
	Yeon Hee Park	(Samsung Medical Center)
	Educational Initiatives of Singapore Society of Oncology
	Eileen Poon	(National Cancer Centre Singapore)
	Oncology Education Initiatives in Taiwan Oncology Society
	Chih-Hung Hsu	(National Taiwan University, College of Medicine, Graduate Institute of Oncology)
	Educational initiative at Japanese Society of Medical Oncology (JSMO): 2025 update
	Ichiro Kinoshita	(Division of Clinical Genomics, Department of Medical Oncology, Hokkaido University Hospital)

March 6 (Thursday)14:00–15:30
Room 14 (Kobe International Exhibition Hall, Hall No.2 Building 3F 3A Meeting Room)

Session Information

Chair	Teruhisa Azuma	(Nara Prefecture General Medical Center)
	Takako Nakajima	(Department of Early Clinical Development, Kyoto University Graduate School of Medicine)
Keynote Lecture
	Potential Contributions of Generative AI to Clinical Oncology
	Hiromizu Takahashi	(Juntendo University Urayasu Hospital, Department of General Medicine)
	Expectations for AI in Drug Development
	Takeshi Sawada	(Kyoto University Hospital)
Discussant	AI and young doctors
	Yosuke Kito	(Ishikawa Prefectural Central Hospital)
	Oncologist working in a medically underserved area, pioneering with AI
	Takuji Seo	(Seo Clinic)
	Reiji Namba	(Kochi Health Sciences Center)

March 6 (Thursday)16:00–17:30
Room 14 (Kobe International Exhibition Hall, Hall No.2 Building 3F 3A Meeting Room)

Session Information

Chair	How do we communicate the appeal of Medical Oncology?
	Yu Sunakawa	(Department of Clinical Oncology, St.Marianna University School of Medicine)
	Tomoko Yamazaki	(Saitama Medical University International Medical Center)
Keynote Speaker
	Seisyou Kou	(Medical Education Development and Research, Department of Medical Education and Humanities, St. Marianna University School of Medicine)
Discussant	Makiko Ono	(Department of Medical Oncology Advanced Medical Development Center Japanese Foundation for Cancer Research Cancer Institute Hospital)
	Hidetoshi Hayashi	(Department of Medical Oncology, Kindai University)
Reporting	Yu Sunakawa	(Department of Clinical Oncology, St. Marianna University School of Medicine)

March 7 (Friday)9:50–11:20
Room 14 (Kobe International Exhibition Hall, Hall No.2 Building 3F 3A Meeting Room)

Session Information

Chair	Haruko Daga	(Osaka City General Hospital)
	Teruhisa Azuma	(Nara Prefecture General Medical Center)
Panelist	Kota Tokunaga	(School of Medicine, Nagoya University)
	Career Development and Work Style Reform: From a Doctor's Point of View
	Shigemasa Takamizawa	(Department of Medical Oncology, NTT Medical Center Tokyo)
	Work Style Reform Initiatives by Pharmacists in University Hospitals: Background and Achievements
	Kanako Azuma	(Tokyo Medical University Hospital)
	Effects and Challenges of Task Shifting from a Nurse's Perspective
	Rieko Nakamura	(Departmen of Nursing, Osaka City General Hospital)

March 7 (Friday)15:00–16:30
Room 14 (Kobe International Exhibition Hall, Hall No.2 Building 3F 3A Meeting Room)

Session Information

Chair	Yukari Tsubata	(Shimane University Hospital)
	Hiroshi Yamamoto	(Department of Respiratory Medicine, Tokyo Metropolitan Institute for Geriatrics and Gerontology)
Keynote Speaker
	Takuma Kato	(Department of Urology, Faculty of medicine, Kagawa University)
	Ayako Doi	(Department of Medical Oncology, Tonan Hospital)
	Masato Ozaka	(Cancer Institute Hospital of JFCR)
Discussant	Yukiyoshi Fujita	(Depertment of Pharmacy, Gunma Prefectural Cancer Center)
	Yoshiko Kitagawa	(Nursing Department, NHO Kyushu Cancer Center)
	Kazuyo Nakamura	(Department of Pharmacy, Shizuoka General Hospital)
	Takako Oji	(Kobe City Medical Center West Hospital)